Search clinical trials for: Placebo (NNC0268-0965)

Total 53487 results

Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Recruiting

A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Healthy Volunteers - Liver Diseases

United Kingdom
Novo Nordisk A/S

Completed

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Chengdu Suncadia Medicine Co., Ltd.

Recruiting

Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency

Glomerulonephritis

China
FORUM Pharmaceuticals Inc
Parexel

Completed

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Healthy | Growth Hormone Disorder

Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

Healthy Subjects

United States
Pfizer

Completed

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

Glucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects

Healthy Subjects

Japan
Indalo Therapeutics, Inc.

Terminated

A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Healthy Volunteers

United Kingdom
Chengdu Suncadia Medicine Co., Ltd.

Not yet recruiting

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

Primary IgA Nephropathy
Novo Nordisk A/S

Completed

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
NS Pharma, Inc.
Cooperative International Neuromuscular Research Group; Nippon Shinyaku Co.... and other collaborators

Completed

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada
Chengdu Suncadia Medicine Co., Ltd.

Recruiting

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

China
Novo Nordisk A/S

Completed

A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1)

Healthy Volunteers | Haemophilia A With or Without Inhibitors

United States, Germany, Spain, Austria, Bulgaria, Italy, Japan, South Africa, Switzerland, Turkey, United Kingdom, Poland
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Taiwan, China, United States, United Kingdom, Netherlands, Spain, Australia, Norway, Russian Federation, Greece, Italy, Turkey, Mexico, Canada, Hong Kong, New Zealand, Ukraine
Novo Nordisk A/S

Completed

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

Haemophilia A

Germany
Novo Nordisk A/S

Completed

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Obesity

United States
Novo Nordisk A/S

Completed

Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

Healthy | Growth Hormone Disorder

Denmark
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Chengdu Suncadia Medicine Co., Ltd.

Active, not recruiting

Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

China
National Institute of Diabetes and Digestive and...
Novo Nordisk A/S

Active, not recruiting

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 (TOPPLE T1D)

Type I Diabetes

United States
Alyssum Therapeutics
CBCC Global Research

Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Solid Tumor

United States
Pfizer

Completed

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Active, not recruiting

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) (FRONTIER 5)

Haemophilia A With Inhibitors | Haemophilia A

Spain, Korea, Republic of, Canada, United Kingdom, United States, Germany, South Africa, Italy, Austria, Belgium, France, Japan
Novo Nordisk A/S

Recruiting

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

Haemophilia A With Inhibitors | Haemophilia A

United States, Korea, Republic of, France, Spain, Romania, Canada, Taiwan, China, Lithuania, Netherlands, India, South Africa, Russian Federation, Austria, Belgium, Czechia, Denmark, Germany, Ireland, Italy, Japan, Latvia, Malaysia, M... and more
Novo Nordisk A/S

Completed

A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone

Growth Hormone Disorder | Growth Hormone Deficiency in Children

Israel, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
National Center of Neurology and Psychiatry, Japan
Nippon Shinyaku Co., Ltd.

Completed

Exploratory Study of NS-065/NCNP-01 in DMD

Duchenne Muscular Dystrophy

Japan
NS Pharma, Inc.
Cooperative International Neuromuscular Research Group; Nippon Shinyaku Co.... and other collaborators

Completed

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
NS Pharma, Inc.

Approved for marketing

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

Muscular Dystrophy, Duchenne | DMD
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Duchenne Muscular Dystrophy

Spain, United States, Russian Federation, Italy, China, Turkey
Herantis Pharma Plc.
Clinical Research Services Turku - CRST Oy

Completed

Single Ascending Doses of HER-096 in Healthy Subjects

Parkinson Disease

Finland
Novo Nordisk A/S

Terminated

Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

Cancer | Malignant Melanoma

Germany
Pfizer

Terminated

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

Plaque Psoriasis

United States, Canada
Johnson & Johnson Consumer and Personal Products...

Completed

A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions

Coitus

United States
Merck Sharp & Dohme LLC

Completed

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

Chronic Lymphocytic Leukemia (CLL)
Novo Nordisk A/S

Completed

Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark
Novo Nordisk A/S

Completed

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works

Diabetes Mellitus, Type 1

Austria
CHU de Quebec-Universite Laval

Completed

Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy

Ureteral Injury

Canada
AbbVie
Merck Sharp & Dohme LLC

Terminated

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Cancer - Acute Myeloid Leukemia

United States, Australia, Spain
University Hospital, Ghent

Withdrawn

Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure

Hydration of Scars

Belgium

Search clinical trials for: Placebo (NNC0268-0965)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations